Pregnancy and Lactation. The University shall provide reasonable accommodations for pregnancy or pregnancy-related conditions (examples include but are not limited to, morning sickness and lactation) unless to do so would impose an undue hardship on the University. Examples of such accommodations include, but are not limited to, a modified work schedule; more frequent restroom, food, or water breaks; providing equipment for seating; limits on lifting; more frequent or longer paid or unpaid breaks; time off, with or without pay, to attend to a pregnancy-related complication; private non-bathroom space for expressing breast milk; and assistance with manual labor. No such accommodations can result in decreased pay or benefits for the SW. The University provides many lactation rooms across the University. Any nursing SW or their spouses/partners who are breastfeeding can register to use a Harvard lactation room. Locations of such lactation rooms can be found on the XXXXxx website.
Pregnancy and Lactation. Do not prescribe to pregnant or breastfeeding women.
Pregnancy and Lactation. [*] [*] Confidential treatment requested; certain information omitted and filed separately with the SEC. Xxxxxx® (vapreotide acetate) Version 1.0
Pregnancy and Lactation. Very little data available on safety. Avoid unless the risk of drinking without it is so high that the benefit of naltrexone outweighs the risks. Avoid during breastfeeding.
Pregnancy and Lactation. Acamprosate should not be prescribed in pregnant or breastfeeding patients and should be discontinued if pregnancy occurs.
Pregnancy and Lactation. There is no relevant clinical experience with KTE-X19 in pregnant or lactating women, and animal reproductive studies have not been performed. Women of child bearing potential must have a negative pregnancy test prior to enrollment because of the potentially dangerous effects of the preparative chemotherapy on the fetus. Women of childbearing potential should be monitored according to local and country-specific regulations. This experimental therapy should not be administered to pregnant women or women who are breastfeeding. If a pregnancy occurs in a female subject enrolled into the study, or a female partner of a male subject within 6 months of completing the KTE-X19 infusion, the pregnancy must be reported to the key sponsor contact. Information regarding the pregnancy and/or the outcome may be requested by the key sponsor. In addition to reporting any pregnancies occurring during the study, investigators should monitor for pregnancies that occur after the last dose of conditioning chemotherapy through 6 months for female subjects and for 6 months for the female partner of the male subjects. The pregnancy should be reported to the key sponsor contact within 24 hours of the investigators knowledge of the pregnancy event. If a lactation case occurs while the female subject is taking protocol required therapies report the lactation case to the key sponsor contact. In addition to reporting a lactation case during the study, investigators should monitor for lactation cases that occur after the last dose of protocol required therapies through 6 months. Any lactation case should be reported to the key sponsor contact within 24 hours of the investigator’s knowledge of the event.
Pregnancy and Lactation. Mycophenolate mofetil, mycophenolic acid: new pregnancy-prevention advice for women and men Mycophenolate mofetil and its active metabolite mycophenolic acid are associated with a high rate of serious birth defects and increased risk of spontaneous abortion. xxxxx://xxx.xxx.xx/government/uploads/system/uploads/attachment_data/file/485099/Drug_Safety_Update_ Dec_2015.pdf Mycophenolate mofetil or mycophenolic acid should not be used in pregnancy unless there is no suitable alternative treatment to prevent transplant rejection Physicians should ensure that women and men taking mycophenolate mofetil and mycophenolic acid understand: the risk of harm to a baby; the need for effective contraception; the need to plan for pregnancy and change treatment as necessary; and the need to immediately consult a physician if there is a possibility of pregnancy Mycophenolate mofetil or mycophenolic acid treatment should only be initiated in women of child bearing potential when there is a negative pregnancy test result to rule out unintended use in pregnancy. Two serum or urine pregnancy tests with a sensitivity of at least 25 mIU/mL are recommended. The second test should be done 8–10 days after the first one and immediately before starting mycophenolate mofetil. Pregnancy tests should be repeated as clinically required (eg, after any gap in contraception is reported). Results of all pregnancy tests should be discussed with the patient. Mycophenolate mofetil or mycophenolic acid should only be given to women of childbearing potential who are using highly effective contraception Women should use 2 forms of effective contraception during treatment and for 6 weeks after stopping treatment Men (including those who have had a vasectomy) should use condoms during treatment and for at least 90 days after stopping treatment. This advice is a precautionary measure due to the genotoxicity of these products . UPDATED CONTRACEPTION ADVICE FOR MALE PATIENTS FEB 18. Female partners of male patients treated with mycophenolate mofetil or mycophenolic acid should use highly effective contraception during treatment and for 90 days after the last dose Patients should be instructed not to stop treatment but to consult their physician immediately should pregnancy occur. Breast feeding is contra-indicated As mycophenolate metabolites undergo extensive enterohepatic recirculation, any drugs which may interfere with this pathway should be avoided: Antacids containing magnesium...
Pregnancy and Lactation. Carboplatin may cause fetal harm; therefore, women of childbearing potential should be advised to avoid becoming pregnant.
Pregnancy and Lactation. Administration during pregnancy should be avoided unless there are compelling reasons for Budenofalk® 2mg rectal foam therapy. In pregnant animals, budesonide, like other glucocorticosteroids, has been shown to cause abnormalities of foetal development. The relevance of this to man has not been established. Since it is not known if budesonide passes into breast milk, the infant should not be breast-fed during treatment with Budenofalk® 2mg rectal foam.
Pregnancy and Lactation. No animal reproductive studies have been conducted. It is not known whether Diacol™ Tablets can cause harm to the unborn foetus if administered to a pregnant woman, or interfere with reproductive capacity. Diacol™ Tablets should not be used during pregnancy or by lactating mothers.
